118 related articles for article (PubMed ID: 23176073)
1. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Viallet F; Pitel S; Lancrenon S; Blin O
Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073
[TBL] [Abstract][Full Text] [Related]
2. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson's Disease.
Seppänen P; Forsberg MM; Tiihonen M; Laitinen H; Beal S; Dorman DC
Parkinsons Dis; 2024; 2024():8448584. PubMed ID: 38264500
[TBL] [Abstract][Full Text] [Related]
4. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
Micallef J; Rey M; Eusebio A; Audebert C; Rouby F; Jouve E; Tardieu S; Blin O
Br J Clin Pharmacol; 2009 Mar; 67(3):333-40. PubMed ID: 19220275
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Olanow CW; Hauser RA; Burdick DJ; Dhall R; de Marcaida JA; Gil RA; Kreitzman DL; Elmer LW; McGarry A; Kieburtz K;
Mov Disord; 2024 Feb; 39(2):350-359. PubMed ID: 37886872
[TBL] [Abstract][Full Text] [Related]
6. Auditory musical hallucinations associated with extended-release pramipexole in an elderly patient with Parkinson's disease.
Kataoka H; Ueno S
Medicine (Baltimore); 2014 Dec; 93(27):e251. PubMed ID: 25501095
[TBL] [Abstract][Full Text] [Related]
7. Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
Arpin DJ; Mitchell T; Archer DB; Burciu RG; Chu WT; Gao H; Guttuso T; Hess CW; Lai S; Malaty IA; McFarland NR; Pasternak O; Price CC; Shukla AW; Wu SS; Okun MS; Vaillancourt DE
Mov Disord; 2022 Feb; 37(2):325-333. PubMed ID: 34724257
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of rasagiline in patients with Parkinson's disease in Japan: a post-marketing surveillance study.
Hattori N; Kajita M; Fujimoto S; Izutsu M; Fernandez J
Expert Opin Drug Saf; 2024 Jan; 23(1):79-88. PubMed ID: 38124528
[TBL] [Abstract][Full Text] [Related]
9. The effect of rasagiline on swallowing function in Parkinson's disease.
Hirano M; Samukawa M; Isono C; Kusunoki S; Nagai Y
Heliyon; 2024 Jan; 10(1):e23407. PubMed ID: 38187336
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
Márquez-Cruz M; Díaz-Martínez JP; Soto-Molina H; De Saráchaga AJ; Cervantes-Arriaga A; Llorens-Arenas R; Rodríguez-Violante M
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):97-102. PubMed ID: 26731410
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
Cai JP; Chen WJ; Lin Y; Cai B; Wang N
Eur Neurol; 2015; 73(1-2):5-12. PubMed ID: 25358603
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
Mendzelevski B; Sprenger CR; Spiegelstein O; Rabinovich-Guilatt L
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):192-201. PubMed ID: 24447649
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
[TBL] [Abstract][Full Text] [Related]
16. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
Schrempf W; Fauser M; Wienecke M; Brown S; Maaß A; Ossig C; Otto K; Brandt MD; Löhle M; Schwanebeck U; Graehlert X; Reichmann H; Storch A
Eur J Neurol; 2018 Apr; 25(4):672-679. PubMed ID: 29322594
[TBL] [Abstract][Full Text] [Related]
17. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
Schapira AH; McDermott MP; Barone P; Comella CL; Albrecht S; Hsu HH; Massey DH; Mizuno Y; Poewe W; Rascol O; Marek K
Lancet Neurol; 2013 Aug; 12(8):747-55. PubMed ID: 23726851
[TBL] [Abstract][Full Text] [Related]
20. Rapid onset of efficacy of rasagiline in early Parkinson's disease.
Zambito Marsala S; Vitaliani R; Volpe D; Capozzoli F; Baroni L; Belgrado E; Borsato C; Gioulis M; Marchini C; Antonini A
Neurol Sci; 2013 Nov; 34(11):2007-13. PubMed ID: 23636872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
